Therapeutic agent

Lumbrokinase

PreliminaryEvidence level
1Registered trials
2Conditions
0Study references

Evidence Summary

Evidence Level
Preliminary
Mechanism
Enrollment: Estimated, Sponsor Type: Other, Unknown / General
Safety
Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing
See linked studies/trials for reported doses and durations; typical protocols vary widely.
Mount Sinai RCT recruiting (NCT06511050) for microclots in Long COVID/ME-CFS. Fibrinolytic. 20-40mg 2-3x/day protocols. Low bleeding risk but caution with anticoagulants. Rigorous trial underway; currently research-only.

Clinical Trials

1 trial(s) registered

NCT IDTitlePhaseStatus
NCT06511050Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue SyndromePhase 1Recruiting

Key Studies / References

  • See linked studies